GSK983
Based on 1 Customer Validation
GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes.
For research use only. We do not sell to patients.
- Purity : 99.8%
- CAS No.: 827591-02-6
- Formula: C18H16ClN3O
- Molecular Weight:325.79
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HFF | CC50 |
16 μM
Compound: 41
|
Cytotoxicity against HFF cells
Cytotoxicity against HFF cells
|
[PMID: 19556128] |
In Vitro
GSK983 (0-10000 nM; 2 h) inhibits replication of adenovirus-5 (Ad-5) in primary human fibroblasts (HFF) and polyoma virus SV40 in Vero cells with the median effect concentration (K) of 21 nM, 7.5 nM; and maximum inhibition (I max) of 99%, 88%, respectively[1].
GSK983 (0-10000 nM; 72 h) inhibits the growth of cell lines immortalized by viral infection with the median effect concentration (K) of 16, 14, 7.5 nM for IM9 (EBV), B-LCL 5/2/1 (EBV), MT4 (HTLV1) cells, respectively[1].
GSK983 (10, 100 nM; 24, 48 h) induces the expression of interferon-stimulated genes in W12, HKC cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:W12, HKC cells
-
Concentration:10, 100 nM
-
Incubation Time:24, 48 h
-
Result:Induced the expression of interferon-stimulated genes in infected and immortalized cells, increased the gene expression of CSF2, IFIT1 (ISG56), IL6, ISG15, OAS1, OAS2, OASL and TNFSF10 (TRAIL).
Chemical Information
-
CAS No. 827591-02-6
-
Appearance Solid
-
Molecular Weight 325.79
-
Formula C18H16ClN3O
-
Color White to light yellow
-
SMILES
O=C(C1=NC=CC=C1)N[C@H]2C3=C(CCC2)C(C=C(C=C4)Cl)=C4N3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : ≥ 10 mg/mL (30.69 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0695 mL | 15.3473 mL | 30.6946 mL | 76.7365 mL |
| 5 mM | 0.6139 mL | 3.0695 mL | 6.1389 mL | 15.3473 mL | |
| 10 mM | 0.3069 mL | 1.5347 mL | 3.0695 mL | 7.6737 mL | |
| 15 mM | 0.2046 mL | 1.0232 mL | 2.0463 mL | 5.1158 mL | |
| 20 mM | 0.1535 mL | 0.7674 mL | 1.5347 mL | 3.8368 mL | |
| 25 mM | 0.1228 mL | 0.6139 mL | 1.2278 mL | 3.0695 mL | |
| 30 mM | 0.1023 mL | 0.5116 mL | 1.0232 mL | 2.5579 mL |